Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More
Drugs Health Pharma

Alexion, Pfizer sign $1 billion accord for genomic medicines

HQ Team July 29, 2023: Alexion, AstraZeneca Rare Disease, an arm of AstraZeneca group, has signed a $1 billion pact with Pfizer for.

Read More